These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 11750350)
21. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients. Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336 [No Abstract] [Full Text] [Related]
22. Cyclosporine level: which single-point estimation of drug level is the best? Sharma R; Kumar J; Ahmed M; Gupta A; Gulati S; Sharma AP; Bhandari M Transplant Proc; 2001; 33(7-8):3124-5. PubMed ID: 11750343 [No Abstract] [Full Text] [Related]
23. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. Einecke G; Mai I; Diekmann F; Fritsche L; Neumayer HH; Budde K Transplant Proc; 2002 Aug; 34(5):1738-9. PubMed ID: 12176557 [No Abstract] [Full Text] [Related]
24. Neoral dose monitoring with cyclosporine 2-hour postdose levels (C(2)) in different renal transplant patient age groups. Rosati A; Bertoni E; Zanazzi M; Di Maria L; Ciuti R; Piperno R; Moscarelli L; Biagini M; Salvadori M Transplant Proc; 2001; 33(7-8):3106-7. PubMed ID: 11750335 [No Abstract] [Full Text] [Related]
25. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? Gaspari F; Caruso R; Cattaneo D; Perico N; Remuzzi G Transplant Proc; 2001; 33(7-8):3117-9. PubMed ID: 11750340 [No Abstract] [Full Text] [Related]
26. Cyclosporine blood concentration at 2 hours (C(2)) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients--a four-year follow-up. Baczkowska T; Serafinowicz A; Kukuła K; Nowacka-Cieciura E; Cieciura T; Deborska D; Gałazka Z; Rowiński W; Szmidt J; Durlik M; Lao M Transplant Proc; 2002 Mar; 34(2):556-7. PubMed ID: 12009622 [No Abstract] [Full Text] [Related]
27. Neoral monitoring: limitations of trough level monitoring and the potential role of limited sampling strategies. Cole EH Transplant Proc; 2000 Nov; 32(7):1556-8. PubMed ID: 11119832 [No Abstract] [Full Text] [Related]
28. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice. Vathsala A; Lu YM Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348 [No Abstract] [Full Text] [Related]
29. Cyclosporine peak concentration in relation to the four-hour absorption phase in pediatric renal graft recipients. Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R Transplant Proc; 2001; 33(7-8):3126-7. PubMed ID: 11750344 [No Abstract] [Full Text] [Related]
30. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral). Foradori A; Pinto VM; Elberg A Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235 [No Abstract] [Full Text] [Related]
31. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2. Cole E; Deshpande R Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376 [TBL] [Abstract][Full Text] [Related]
32. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients. Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379 [No Abstract] [Full Text] [Related]
33. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. Einecke G; Mai I; Diekmann F; Fritsche L; Boehler T; Neumayer HH; Budde K Transplant Proc; 2001; 33(7-8):3102-3. PubMed ID: 11750333 [No Abstract] [Full Text] [Related]
34. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. Balram C; Sivathasan C; Cheung YB; Tan SB; Tan YS J Heart Lung Transplant; 2002 Sep; 21(9):1016-21. PubMed ID: 12231373 [TBL] [Abstract][Full Text] [Related]
35. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Foradori A; Mezzano S; Videla C; Pefaur J; Elberg A Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244 [No Abstract] [Full Text] [Related]
36. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group. Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231 [No Abstract] [Full Text] [Related]
37. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients. Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936 [TBL] [Abstract][Full Text] [Related]
38. Optimization of cyclosporine therapy in kidney transplantation. Remuzzi G; Perico N; Gaspari F Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238 [No Abstract] [Full Text] [Related]
39. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome. Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243 [No Abstract] [Full Text] [Related]
40. Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients. Jaiswal J; Gupta SK; Dash SC; Tiwari SC; Mehta SN; Gupta YK; Velpandian T Transplant Proc; 2003 Jun; 35(4):1298-9. PubMed ID: 12826142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]